Overactive Bladder Clinical Trial
Official title:
Pivotal Study of Subcutaneous Tibial Nerve Stimulation With eCoin for Overactive Bladder (OAB) With Urgency Urinary Incontinence (UUI)
Verified date | January 2024 |
Source | Valencia Technologies Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.
Status | Active, not recruiting |
Enrollment | 133 |
Est. completion date | April 28, 2024 |
Est. primary completion date | April 12, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Primary Inclusion Criteria: 1. Women and men between 18 and 80 years old. 2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component (selfreported), for at least 6 months. 3. Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists). 4. Individual is intolerant of or has an inadequate response to any of anticholinergics, ß3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous tibial nerve stimulation. Primary Exclusion Criteria: 1. Predominant stress urinary incontinence with more than 1/3 stress urinary incontinent episodes when compared to total urinary incontinent episodes. 2. Clinically significant bladder outlet obstruction. 3. Clinically significant pelvic organ prolapse beyond the hymenal ring. 4. Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg. |
Country | Name | City | State |
---|---|---|---|
United States | The Institute for Female Pelvic Medicine & Reconstructive Surgery (FPM Institute) | Allentown | Pennsylvania |
United States | South Carolina OB/GYN | Columbia | South Carolina |
United States | Kaiser Permanente | Downey | California |
United States | SurgOne PC | Englewood | Colorado |
United States | Alliance Urology Specialists | Greensboro | North Carolina |
United States | Florida Bladder Institute | Naples | Florida |
United States | Manhattan Medical Research | New York | New York |
United States | Urology Associates of Norwalk | Norwalk | Connecticut |
United States | Adult & Pediatric Urology | Omaha | Nebraska |
United States | Chesapeake Urology | Owings Mills | Maryland |
United States | Sequoia Urology Center | Redwood City | California |
United States | Kaiser Permanente | San Diego | California |
United States | Sansum Clinic | Santa Barbara | California |
United States | North Shore Medical Group | Skokie | Illinois |
United States | UnityPoint Clinic | Waterloo | Iowa |
Lead Sponsor | Collaborator |
---|---|
Valencia Technologies Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | Responder rate | 48 weeks after device activation. | |
Primary | Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events. | All adverse events will be reported in all patients who were implanted 12 months after implantation. | 52 weeks after implantation. | |
Secondary | Moderate-term Safety in All Patients. Percentage of Patients With Device or Implantation Related Adverse Events. | All adverse events will be reported. | 24 weeks after device activation | |
Secondary | Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | Moderate-term effectiveness data, responder rate | 24 weeks after device activation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Completed |
NCT02667470 -
Reproducibility Study of OABSS and Its Response to Treatment
|
Phase 4 | |
Completed |
NCT00928070 -
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
|
Phase 4 |